BioNTech news - the latest biotech news from Labiotech.eu

Cancer vaccines: 10 biotech companies that have changed the game

Roohi Mariam Peter — Thu, 06 Apr 2023 10:46:21 +0000

A kind of immunotherapy, cancer vaccines have been around since the link between human papillomavirus (HPV) and cancer was discovered in the 1980s. For the prevention of cancers – cervical, vaginal, vulvar and anal cancers – caused by the virus, vaccines were developed, and later approved by the Food and Drug Administration (FDA). Besides the […]

The post Cancer vaccines: 10 biotech companies that have changed the game appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Jim Cornall — Tue, 04 Apr 2023 10:44:43 +0000

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

The post BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal appeared first on Labiotech.eu.

Innovation in life sciences requires collaboration and community

External Contributor — Wed, 18 Jan 2023 17:15:07 +0000

By Claudia Tripp and Katie Nelson, Kadans Science Partner Collaboration has underpinned some of the most impactful innovations of recent years. For example, the rapid development of the COVID vaccine was only made possible due to collaboration. Pfizer’s rapidly-established partnership with BioNTech delivered the first vaccine at lightning speed. Having established an ecosystem approach to […]

The post Innovation in life sciences requires collaboration and community appeared first on Labiotech.eu.

BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies

Jim Cornall — Fri, 06 Jan 2023 09:09:41 +0000

BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […]

The post BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies appeared first on Labiotech.eu.

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Liza Laws — Fri, 26 Aug 2022 14:32:12 +0000

Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine Comirnaty infringes patents it led between 2010 and 2016 covering Moderna’s foundational mRNA technology which the company says was critical to the development of its own […]

The post Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology” appeared first on Labiotech.eu.

Macao university research finds mRNA vaccine booster offers more protection against Omicron variants

Jim Cornall — Mon, 25 Jul 2022 08:38:40 +0000

A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […]

The post Macao university research finds mRNA vaccine booster offers more protection against Omicron variants appeared first on Labiotech.eu.

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

Helen Albert — Mon, 04 Jul 2022 08:42:56 +0000

As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […]

The post The COVID-19 pandemic has driven RNA therapeutics into the mainstream appeared first on Labiotech.eu.

Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials

Jonathan Smith — Tue, 15 Feb 2022 11:16:00 +0000

Despite the widespread rollout of vaccines over 2021, the Covid-19 pandemic remains a threat to healthcare systems worldwide. Numerous treatments and vaccines are hitting the late-stage pipeline, which could greatly expand the anti-Covid-19 arsenal. Two years ago, the Covid-19 pandemic swept the world and left economic disruption, healthcare crises, and widespread lockdowns in its wake. […]

The post Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials appeared first on Labiotech.eu.

The Billion-Euro European Biotech Companies in 2022

Larissa Warneck-Silvestrin — Mon, 20 Dec 2021 10:15:00 +0000

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

The post The Billion-Euro European Biotech Companies in 2022 appeared first on Labiotech.eu.

Delayed IPOs and Market Drops Batter Biotech Stocks

Jonathan Smith — Tue, 25 May 2021 14:31:56 +0000

Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […]

The post Delayed IPOs and Market Drops Batter Biotech Stocks appeared first on Labiotech.eu.

The 21 European Biotech Companies To Watch in 2021

Larissa Warneck-Silvestrin — Mon, 11 Jan 2021 14:33:41 +0000

As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]

The post The 21 European Biotech Companies To Watch in 2021 appeared first on Labiotech.eu.

A Year to Remember: The Biggest European Biotech News in 2020

Jonathan Smith — Mon, 28 Dec 2020 08:00:42 +0000

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]

The post A Year to Remember: The Biggest European Biotech News in 2020 appeared first on Labiotech.eu.

EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19

Jonathan Smith — Tue, 22 Dec 2020 11:10:36 +0000

BioNTech and Pfizer’s Covid-19 vaccine, made from messenger RNA, has become the first of its kind to be approved by the EMA. The EMA has granted conditional approval to Comirnaty, a vaccine against Covid-19 developed by BioNTech and Pfizer. The approval comes weeks after the UK became the first country in the world to approve […]

The post EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19 appeared first on Labiotech.eu.

mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine

Jonathan Smith — Thu, 19 Nov 2020 15:04:18 +0000

The field of messenger RNA therapeutics is flying high as BioNTech and Pfizer conclude a phase III trial with their Covid-19 vaccine showing 95% effectiveness. The phase III trial recruited over 43,000 volunteers to gauge whether Covid-19 infections could be prevented by a vaccine made out of messenger RNA (mRNA). One group received two doses […]

The post mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine appeared first on Labiotech.eu.

Pfizer-BioNTech Covid-19 Vaccine Shows Phase I Promise

Victor Kotsev — Fri, 03 Jul 2020 15:46:08 +0000

A vaccine made out of messenger RNA (mRNA), developed by the US pharmaceutical giant Pfizer and its German partner BioNTech, has produced antibodies against the Covid-19 pathogen in healthy volunteers. The results come from an interim analysis of an ongoing phase I clinical trial in 45 participants. So far, all test subjects who received two […]

The post Pfizer-BioNTech Covid-19 Vaccine Shows Phase I Promise appeared first on Labiotech.eu.

Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans

Helen Albert — Wed, 29 Apr 2020 14:20:23 +0000

Update (29/04/2020): A vaccine developed by the German company BioNTech and its big pharma partner Pfizer has become the first European mRNA vaccine for Covid-19 to enter human testing in a phase I/II trial. Since dosing began last week, twelve volunteers in Germany have been given the vaccine. The first part of the trial — […]

The post Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans appeared first on Labiotech.eu.

Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?

Jonathan Smith — Mon, 30 Mar 2020 17:31:36 +0000

The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […]

The post Could mRNA Vaccines Fulfill Their Potential Against Coronavirus? appeared first on Labiotech.eu.

BioNTech Expands Cancer Portfolio With US Biotech Acquisition

Helen Albert — Thu, 16 Jan 2020 16:31:34 +0000

German cancer specialist BioNTech will acquire US T-cell therapy biotech Neon Therapeutics in a deal worth €60M, both to expand its cancer therapy pipeline and establish a US base. The deal is expected to complete in the second half of 2020, after which Neon will operate as a subsidiary of BioNTech. BioNTech has arguably scooped […]

The post BioNTech Expands Cancer Portfolio With US Biotech Acquisition appeared first on Labiotech.eu.

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

Jonathan Smith — Mon, 06 Jan 2020 15:51:45 +0000

A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […]

The post BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice appeared first on Labiotech.eu.

How BioNTech Navigates the Biotech Fundraising Maze

Helen Albert — Wed, 18 Dec 2019 14:13:30 +0000

BioNTech is on a mission to individualize cancer therapy by developing a range of different innovative therapies, a task that can be a rollercoaster ride, according to its Chief Business and Commercial Officer Sean Marett. It’s been an interesting year for the German biotech. In July the company raised one of the biggest ever European […]

The post How BioNTech Navigates the Biotech Fundraising Maze appeared first on Labiotech.eu.